Vaccination challenges and strategies against long-lived Toxoplasma gondii

Fei Kean Loh, Sheila Nathan, Sek Chuen Chow, Chee Mun Fang

Research output: Contribution to journalReview article

Abstract

Since the discovery of Toxoplasma gondii in 1908, it is estimated that one-third of the global population has been exposed to this ubiquitous intracellular protozoan. The complex life cycle of T. gondii has enabled itself to overcome stress and transmit easily within a broad host range thus achieving a high seroprevalence worldwide. To date, toxoplasmosis remains one of the most prevalent HIV-associated opportunistic central nervous system infections. This review presents a comprehensive overview of different vaccination approaches ranging from traditional inactivated whole-T. gondii vaccines to the popular DNA vaccines. Extensive discussions are made to highlight the challenges in constructing these vaccines, selecting adjuvants as well as delivery methods, immunisation approaches and developing study models. Herein we also deliberate over the latest and promising enhancement strategies that can address the limitations in developing an effective T. gondii prophylactic vaccine.

Original languageEnglish
Pages (from-to)3989-4000
Number of pages12
JournalVaccine
Volume37
Issue number30
DOIs
Publication statusPublished - 9 Jul 2019

Fingerprint

Toxoplasma
Toxoplasma gondii
Vaccination
vaccination
Vaccines
vaccines
Central Nervous System Infections
vaccine adjuvants
DNA Vaccines
Host Specificity
toxoplasmosis
Toxoplasmosis
Seroepidemiologic Studies
recombinant vaccines
Life Cycle Stages
host range
seroprevalence
central nervous system
Protozoa
Immunization

Keywords

  • Cross-protection
  • Life cycle
  • Toxoplasma gondii
  • Vaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Vaccination challenges and strategies against long-lived Toxoplasma gondii. / Loh, Fei Kean; Nathan, Sheila; Chow, Sek Chuen; Fang, Chee Mun.

In: Vaccine, Vol. 37, No. 30, 09.07.2019, p. 3989-4000.

Research output: Contribution to journalReview article

Loh, Fei Kean ; Nathan, Sheila ; Chow, Sek Chuen ; Fang, Chee Mun. / Vaccination challenges and strategies against long-lived Toxoplasma gondii. In: Vaccine. 2019 ; Vol. 37, No. 30. pp. 3989-4000.
@article{3d4c8e6fc11b45edb7683f916908a532,
title = "Vaccination challenges and strategies against long-lived Toxoplasma gondii",
abstract = "Since the discovery of Toxoplasma gondii in 1908, it is estimated that one-third of the global population has been exposed to this ubiquitous intracellular protozoan. The complex life cycle of T. gondii has enabled itself to overcome stress and transmit easily within a broad host range thus achieving a high seroprevalence worldwide. To date, toxoplasmosis remains one of the most prevalent HIV-associated opportunistic central nervous system infections. This review presents a comprehensive overview of different vaccination approaches ranging from traditional inactivated whole-T. gondii vaccines to the popular DNA vaccines. Extensive discussions are made to highlight the challenges in constructing these vaccines, selecting adjuvants as well as delivery methods, immunisation approaches and developing study models. Herein we also deliberate over the latest and promising enhancement strategies that can address the limitations in developing an effective T. gondii prophylactic vaccine.",
keywords = "Cross-protection, Life cycle, Toxoplasma gondii, Vaccination",
author = "Loh, {Fei Kean} and Sheila Nathan and Chow, {Sek Chuen} and Fang, {Chee Mun}",
year = "2019",
month = "7",
day = "9",
doi = "10.1016/j.vaccine.2019.05.083",
language = "English",
volume = "37",
pages = "3989--4000",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "30",

}

TY - JOUR

T1 - Vaccination challenges and strategies against long-lived Toxoplasma gondii

AU - Loh, Fei Kean

AU - Nathan, Sheila

AU - Chow, Sek Chuen

AU - Fang, Chee Mun

PY - 2019/7/9

Y1 - 2019/7/9

N2 - Since the discovery of Toxoplasma gondii in 1908, it is estimated that one-third of the global population has been exposed to this ubiquitous intracellular protozoan. The complex life cycle of T. gondii has enabled itself to overcome stress and transmit easily within a broad host range thus achieving a high seroprevalence worldwide. To date, toxoplasmosis remains one of the most prevalent HIV-associated opportunistic central nervous system infections. This review presents a comprehensive overview of different vaccination approaches ranging from traditional inactivated whole-T. gondii vaccines to the popular DNA vaccines. Extensive discussions are made to highlight the challenges in constructing these vaccines, selecting adjuvants as well as delivery methods, immunisation approaches and developing study models. Herein we also deliberate over the latest and promising enhancement strategies that can address the limitations in developing an effective T. gondii prophylactic vaccine.

AB - Since the discovery of Toxoplasma gondii in 1908, it is estimated that one-third of the global population has been exposed to this ubiquitous intracellular protozoan. The complex life cycle of T. gondii has enabled itself to overcome stress and transmit easily within a broad host range thus achieving a high seroprevalence worldwide. To date, toxoplasmosis remains one of the most prevalent HIV-associated opportunistic central nervous system infections. This review presents a comprehensive overview of different vaccination approaches ranging from traditional inactivated whole-T. gondii vaccines to the popular DNA vaccines. Extensive discussions are made to highlight the challenges in constructing these vaccines, selecting adjuvants as well as delivery methods, immunisation approaches and developing study models. Herein we also deliberate over the latest and promising enhancement strategies that can address the limitations in developing an effective T. gondii prophylactic vaccine.

KW - Cross-protection

KW - Life cycle

KW - Toxoplasma gondii

KW - Vaccination

UR - http://www.scopus.com/inward/record.url?scp=85067068221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067068221&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.05.083

DO - 10.1016/j.vaccine.2019.05.083

M3 - Review article

C2 - 31186188

AN - SCOPUS:85067068221

VL - 37

SP - 3989

EP - 4000

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 30

ER -